Goodwill (Details)	3 Months Ended		9 Months Ended			6 Months Ended	3 Months Ended		9 Months Ended	45 Months Ended	3 Months Ended
	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2012 Lev Pharmaceuticals, Inc USD ($)	Jun. 30, 2012 Lev Pharmaceuticals, Inc Cinryze USD ($)	Oct. 31, 2008 Lev Pharmaceuticals, Inc Cinryze USD ($)	Sep. 30, 2013 Lev Pharmaceuticals, Inc Cinryze Minimum USD ($)	Jun. 30, 2012 Lev Pharmaceuticals, Inc Cinryze Minimum USD ($)	Sep. 30, 2012 DuoCort Pharma AB USD ($)	Sep. 30, 2012 DuoCort Pharma AB SEK	Nov. 30, 2011 DuoCort Pharma AB USD ($)	May 31, 2010 Auralis Limited USD ($)
Goodwill disclosures
Contingent consideration, potential payment per share value								$ 0.50
Contingent consideration, potential cash payment								$ 87,500,000
Sales milestone threshold needed to trigger contingent payment									600,000,000
Actual net product sales	113,062,000	91,004,000	323,922,000	321,444,000						600,000,000
Contingent consideration cash payment				91,404,000		92,300,000
Addition to goodwill							86,300,000
Recognized goodwill on acquisition	96,798,000		96,798,000		96,759,000								7,300,000	5,900,000
Adjustments to goodwill resulting from recognition of deferred tax assets											$ 3,500,000	22,800,000
Ownership interest (as a percent)													100.00%	100.00%